Pharmaceutical Product Development Inc. and Southern Research Institute, Inc. announced that they have formed a collaborative agreement in pandemic and seasonal influenza vaccine research and development to provide clients a full spectrum of influenza vaccine development services by collaborating on client bids and projects. As part of the agreement, Southern Research will transfer its seasonal assays and reagents to PPD, strengthening PPD's influenza vaccine testing services. In return, PPD will help build Southern Research's preclinical influenza and clinical pandemic/highly pathogenic avian influenza (HPAI) testing business through client referrals.

Pharmaceutical Product Development Inc. announced that its board of directors declared a cash dividend for the first quarter of 2010 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share. The record date for the first quarter dividend is March 15, 2010, and the payment date is March 29, 2010.

Pharmaceutical Product Development Inc. Presents at 31st Annual Institutional Investors Conference, Mar-10-2010. Venue: JW Marriott Grande Lakes, Orlando, Florida, United States. Speakers: Daniel G. Darazsdi, Chief Financial Officer, Assistant Secretary and Treasurer, David L. Grange, Chief Executive Officer, Director, Chairman of Nominating & Governance Committee and Member of Compensation Committee, Luke Heagle, Director, Investor Relations.